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The accrual of healthy bone during the critical period of childhood and adolescence sets the
stage for lifelong skeletal health. However, in children with chronic kidney disease (CKD),
disturbances in mineral metabolism and endocrine homeostasis begin early on, leading
to alterations in bone turnover, mineralization, and volume, and impairing growth. Risk
factors for CKD–mineral and bone disorder (CKD–MBD) include nutritional vitamin D defi-
ciency, secondary hyperparathyroidism, increased fibroblast growth factor 23 (FGF-23),
altered growth hormone and insulin-like growth factor-1 axis, delayed puberty, malnutri-
tion, and metabolic acidosis. After kidney transplantation, nutritional vitamin D deficiency,
persistent hyperparathyroidism, tertiary FGF-23 excess, hypophosphatemia, hypomagne-
semia, immunosuppressive therapy, and alteration of sex hormones continue to impair
bone health and growth. As function of the renal allograft declines over time, CKD–MBD
associated changes are reactivated, further impairing bone health. Strategies to optimize
bone health post-transplant include healthy diet, weight-bearing exercise, correction of
vitamin D deficiency and acidosis, electrolyte abnormalities, steroid avoidance, and con-
sideration of recombinant human growth hormone therapy. Other drug therapies have been
used in adult transplant recipients, but there is insufficient evidence for use in the pedi-
atric population at the present time. Future therapies to be explored include anti-FGF-23
antibodies, FGF-23 receptor blockers, and treatments targeting the colonic microbiota by
reduction of generation of bacterial toxins and adsorption of toxic end products that affect
bone mineralization.
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INTRODUCTION
Bone mineralization during childhood and adolescence establishes
the foundation for bone health throughout life, as 90% of bone
mass accrual occurs during the first 20 years. (1). Healthy bone
development requires intricately balanced endocrine and mineral
metabolism. In children with chronic kidney disease (CKD), this
balance is disturbed, as a constellation of CKD-related factors
converge to exert negative effects on bone mineralization, com-
monly resulting in CKD-Mineral and Bone Disorder (CKD-MBD)
prior to transplant. Renal transplantation may correct many of
the underlying CKD risk factors, but introduces new risk factors
as well. Consequently, pediatric renal transplant recipients remain
at increased risk for low bone mineral density (BMD) (2, 3). As
function of the renal allograft declines over time, CKD-specific risk
factors resurface, further impairing bone health. Consequences of
bone disease in children with CKD may include fractures, bone
pain,growth impairment, skeletal deformities, soft-tissue calcifica-
tions, increased risk of cardiovascular disease, and decreased qual-
ity of life and life expectancy. Thus, optimization of bone health is
critical in pediatric patients facing a lifetime with CKD. Pre- and
post-transplant risk factors, current evaluation and management
strategies, as well as emerging future therapies will be reviewed.
BONE DEVELOPMENT AND EVALUATION
In growing children, bone formation is characterized by two dif-
ferent processes: modeling and remodeling. Bone modeling is
unique to growing children; this process promotes new bone for-
mation at sites different from those of bone resorption, resulting in
increase in bone mass, changes in bone dimensions, and longitudi-
nal growth at the growth plate. The new bone formation occurs by
two processes. New cortical bone is deposited around the periph-
ery of the bone by osteoblasts, which form within the periosteum,
and secrete compact bone matrix, resulting in widening of bone
dimensions. Longitudinal growth occurs via endochondral ossi-
fication, the replacement of cartilage of the epiphyseal disks with
new bone. In this process, as older chondrocytes within the epi-
physeal disk die, and osteoblasts enter and lay down new bone
to replace the old cartilage. Meanwhile, chondrocytes continue
to divide and generate new cartilage, and the endochondral ossi-
fication process continues until closure of the epiphyseal plate
occurs at the conclusion of growth. Once peak bone mass has
been reached in early adulthood, bone remodeling becomes dom-
inant and continues throughout life. Bone remodeling is a cyclic
process of bone resorption and formation during which osteo-
clasts break down old bone and osteoblasts replace it with new
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bone at the same site, repairing the microarchitecture of existing
bone, without net accrual of bone mass (4).
As kidney function declines, alterations in mineral and
endocrine homeostasis occur, leading to abnormalities in the bone
modeling and remodeling processes. Traditionally, evaluation of
bone disease in CKD was limited to classification according to
rates of bone turnover (increased bone turn over, decreased bone
turnover or adynamic bone disease, and mixed). However, the
importance of also assessing alterations in skeletal mineralization
and bone volume were recently recognized. Disturbed miner-
alization and/or bone volume can be present in children with
CKD, and associated complications including bone pain, defor-
mities, and fractures may occur even in the setting of normal
bone turnover (5–7). As such, kidney disease improving global
outcome (KDIGO) recommends that the term “CKD-MBD” be
used to describe the broad clinical syndrome encompassing min-
eral, bone, and calcific cardiovascular abnormalities that develop
as a complication of CKD, and the term “renal osteodystrophy” is
restricted to describe bone pathology associated with CKD. The
evaluation and diagnosis of renal osteodystrophy requires bone
biopsy, using a classification system based on parameters of bone
turnover, mineralization, and volume (TMV) (4).
While bone biopsy remains the gold standard for assessment of
bone quality, it is rarely performed in clinical practice due to the
invasive nature of the procedure. Current options for non-invasive
bone imaging include dual X-ray absorptiometry (DXA) and
peripheral quantitative computed tomography (pQCT). DXA is a
two-dimensional technology that measures bone mineral content
(BMC) and bone area (BA), and then calculates areal BMD. DXA
has numerous limitations, most notably the inability to distinguish
between cortical and trabecular bone, and the underestimation of
BMD in shorter individuals. Studies measuring BMD by DXA
in pediatric renal transplant recipients have used height-adjusted
BMD Z -scores to compensate for this limitation (3, 8, 9). pQCT
uses quantitative computed tomography technology to measure
volumetric BMD of peripheral bones. Advantages of pQCT over
DXA technology include the ability to measure true volumetric
bone density, and the ability to differentiate between cortical and
trabecular bone, allowing for geometric measurements of total
cross-sectional area of cortical bone and cortical thickness. The
major disadvantage of pQCT is that it is more costly than DXA.
Radiation exposure from both DXA (0.004–0.005 mSv) and pQCT
(0.01 mSv) is low, however, pQCT radiation exposure is higher
when compared with DXA (10).
Biochemical markers are another available tool for non-invasive
evaluation of bone health. Traditionally, guidelines for children
with CKD recommend routine monitoring of serum levels of
calcium, phosphorus, alkaline phosphatase, and parathyroid hor-
mone (PTH) before and after kidney transplant, but their value as
biomarkers has been limited to the assessment of bone turnover
(11, 12). A recent study used classification and regression tree
analysis to establish biochemical markers as predictors of different
histologic TMV lesions of renal osteodystrophy in pediatric dialy-
sis patients (7). They reported that PTH and alkaline phosphatase
levels <400 IU/L best predicted normal bone turnover and normal
bone mineralization in this population. Higher PTH levels and
lower calcium levels were associated with defective mineralization,
irrespective of bone turnover (7). Another study showed that
hyperparathyroidism was associated with decline in cortical vol-
umetric BMD in children with CKD which was associated with a
fourfold increased fracture risk (13).
Further studies are needed to identify new biomarkers and
establish more precise target ranges for combinations of known
biomarkers that can be used as non-invasive tools for the
evaluation of TMV abnormalities in children with CKD.
CKD-RELATED BONE AND MINERAL CHANGES
Alterations in bone and mineral metabolism begin early in the
course of CKD. Bone histomorphometry shows defective skele-
tal mineralization is present in 29% of children as early as CKD
stage 2, and progresses to 42% at stage 3, and 79% in stage 4
and 5 (14). Among pediatric dialysis patients, histomorphome-
try indicates increased bone turnover in 57% and abnormal bone
mineralization in 48% of the population (7).
Traditional risk factors for CKD–BMD include vitamin D defi-
ciency, secondary hyperparathyroidism, disturbance of the growth
hormone (GH)/insulin-like growth factor-1 (IGF-1) axis, delayed
puberty, malnutrition, and metabolic acidosis. Newer evidence
indicates that fibroblast growth factor 23 (FGF-23) also plays a
key role, and emerging knowledge suggests a role of the colonic
microbiome in bone health.
VITAMIN D, CALCIUM, PHOSPHORUS, AND PTH
Adequate intake of 25(OH)D3 (nutritional vitamin D) and its final
conversion to active 1,25-(OH)2D3 by 1-alpha-hydroxylase in the
kidney, and calcium, phosphorus, and PTH play an important
role in bone health. In children with CKD, the homeostatic mech-
anisms that regulate these are disrupted, leading to development
of secondary hyperparathyroidism and renal osteodystrophy (4).
In the early stages of CKD, production of 1,25-(OH)2D3 may
be impaired by elevated serum phosphorus and loss of 1-alpha-
hydroxylase activity, in conjunction with inhibition of production
and increased degradation of 1,25-(OH)2D3 by FGF-23 (15).
Low 1,25-(OH)2D3 decreases serum calcium levels, leading to
secondary hyperparathyroidism.
In addition, deficiency of nutritional vitamin D contributes to
decreased production of 1,25-(OH)2D3 and is also directly asso-
ciated with more severe secondary hyperparathyroidism along the
entire spectrum of CKD, both before and after kidney transplant.
Even when there is little or no residual 1-alpha-hydroxylase activ-
ity in the late stages of CKD, nutritional vitamin D deficiency leads
to more marked secondary hyperparathyroidism (12, 16).
Dietary phosphorus load is another important determinant
of severity of hyperparathyroidism, beginning in the early CKD
stages, as high dietary phosphorus intake worsens hyperparathy-
roidism, even in the setting of normal serum phosphorus (12).
Conversely, low serum phosphorus levels are also harmful, as
adequate phosphorus balance is required for optimal bone miner-
alization and growth.
The role of PTH as a biomarker of renal osteodystrophy is
an area of intense debate and ongoing research, and its diag-
nostic value is unclear. Based on the available evidence, KDIGO
guidelines recommend maintaining PTH levels with the range of
approximately 2–9 times the upper limit of normal. While the
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optimal target PTH value in CKD is not exactly known, markedly
high or low values can be useful in predicting bone turnover (4).
Further research is needed to establish more precise target ranges,
and to clarify associations with TMV parameters, and outcomes,
such as fracture.
METABOLIC ACIDOSIS
Metabolic acidosis has numerous negative effects on bone health.
It can occur in the early stages of CKD due to underlying tubu-
lar disorders and obstructive uropathies. Additionally, in the late
stages of CKD, as kidney function declines, the ability of the kid-
ney to excrete ammonia is reduced, resulting in metabolic acidosis.
The decrease in systemic pH induces calcium efflux from bones
and increase in urinary calcium excretion, which serves to buffer
hydrogen ions at the expense of bone mineral stores. Chronic
metabolic acidosis inhibits osteoblastic and increases osteoclastic
activity, impairs the incorporation of hydroxyapatite in bone, and
causes resistance to both endogenous and recombinant human
growth hormone (rhGH) (17). Chronic metabolic acidosis also
alters the homeostatic relationships between calcium, PTH, and
1,25-(OH)2D3, promoting excessive bone dissolution (18). Con-
sequences of chronic metabolic acidosis include bone fractures,
reduction in BMD and bone formation rates, and reduced lin-
ear growth (19). Treatment of acidosis with bicarbonate has
been shown to improve hyperparathyroidism and metabolic bone
disease in CKD (20, 21).
GH/IGF-1 AXIS
In children with CKD, disturbances in the GH/IGF-1 axis inter-
fere with normal bone metabolism and growth. The pathogen-
esis involves GH insensitivity, evidenced by inappropriately high
GH levels in the setting of diminished longitudinal growth, and
decreased bioavailability of IGF-1 in patients with CKD. As kidney
function declines in CKD, decreased renal clearance and increased
hepatic production of IGF binding protein occurs. The accu-
mulation of these high-affinity IGF binding proteins bind and
inactivate free IGF-1, resulting in a functional deficiency of bioac-
tive IGF-1, thereby inhibiting the action of IGF-1 on growth plate
chondrocytes resulting in impairment of growth (22).
DELAYED SEXUAL MATURATION AND MALNUTRITION
Sexual maturation is a key determinant of bone mass and strength,
and adequate levels of sex hormones are required for growth and
achievement of peak BMD. Estrogen is essential for accelerating
longitudinal bone growth at the beginning of puberty and for ossi-
fication of cartilage into bone, leading to closure of the epiphyseal
plate at the conclusion of growth in both males and females. Estro-
gen also promotes apoptosis of osteoclasts and inhibits apoptosis
of osteoblasts to inhibit bone breakdown throughout the lifespan
(23). In males, estrogen is produced from testosterone, via the
enzyme aromatase. Testosterone is important for skeletal growth
because of its direct anabolic effects on bone, as well as its ability
to stimulate muscle growth, which puts greater stress on bone to
promote increased bone formation (24).
In children with CKD, testosterone and estrogen production
are impaired, predisposing them to delayed sexual maturation.
The onset of puberty and the pubertal growth spurt in adolescents
with CKD are delayed by 2.5 years on average (25). Studies have
shown that pubertal timing predicts both cortical and trabecular
volumetric BMD in young men, and late puberty is a risk factor
for low BMD and fractures (26). In young women, delayed menar-
che is associated with lower bone density at the lumbar spine and
femoral neck, and declines further with each year that menarche
is delayed (27). A study of pediatric ESRD patients showed that
age at menarche was significantly positively correlated with uremia
duration (28). In boys with CKD and delayed puberty, treatment
with exogenous testosterone resulted in development of sex char-
acteristics and accelerated bone age that exceeded growth velocity,
resulting in lost growth potential (29).
In concert with hypogonadism, malnutrition is also a common
feature of children with CKD that contributes to delayed sexual
maturation and impaired bone development and mineralization
during growth. Poor nutrition and low body fat, or an altered
ratio of lean mass to body fat, delay the adolescent growth spurt
and retard the onset of menarche, as the initiation of menarche
and maintenance of regular menstrual cycles are dependent on
conditions of adequate body fat (30).
Nutritional deficiencies may also directly impact bone miner-
alization and growth. Children with CKD are at risk for macro and
micronutrient deficiencies due to a multitude of factors including
dietary restrictions, appetite suppression related to uremic inflam-
mation and alterations in endocrine and neuropeptide signaling,
and removal of protein, vitamins, and trace elements by dialy-
sis (31). Inadequate dietary intake of calcium and phosphorus
results in the formation of weak, poorly mineralized bone, and
nutritional vitamin D deficiency leads to rickets and osteomalacia
(24). Inadequate dietary intake and low serum levels of the essen-
tial trace elements zinc and copper have been reported in pediatric
CKD and dialysis patients (32, 33). Zinc, which plays an important
role in growth and sexual function, is depleted with dialysis, and
up to 78% of dialysis patients are deficient (34). Zinc deficiency
adversely affects bone metabolism and gonadal function, resulting
in growth retardation and hypogonadism (35). Copper plays an
important role in collagen cross-linking and bone formation, and
copper deficiency is associated with metaphyseal abnormalities,
osteoporosis, and fractures in children (36).
Fibroblast growth factor 23
Newer evidence indicates that FGF-23 plays a key role in the
pathogenesis of renal bone disease during CKD. During early
stages of CKD, alteration in mineral metabolism is marked by
increasing FGF-23 and decreasing levels of co-receptor Klotho,
which act in concert to induce renal phosphate excretion, sup-
press renal 1-alpha-hydroxylase activity, and inhibit PTH secretion
in attempt to maintain phosphorus homeostasis (37–40). As GFR
declines, FGF-23 loses ability to counteract phosphate retention,
but FGF-23 levels continue to rise, reaching elevations of 100- to
1000-fold above normal in dialysis patients (41). This scenario pre-
disposes the patient to tertiary FGF-23 excess and altered mineral
metabolism characterized by post-transplant hypophosphatemia.
A short-term trial studied the effect of early administration of
phosphate binders (sevelamer hydrochloride or calcium acetate)
to normophosphatemic adults with stage 3 and 4 CKD. Results
showed reduction in PTH levels without change in phosphorus or
calcium levels in all patients, and significant decrease in FGF-23
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levels in the group treated with sevelamer hydrochloride. Long-
term studies are needed to determine whether early administration
of phosphate binders to pediatric CKD patients with normal phos-
phate levels may provide long-term benefits to bone health, by
targeting FGF-23 early in the course of CKD (42). Calcimimet-
ics are useful in adults in controlling hyperparathyroidism but are
not currently approved for use in children, as safety and long-term
effects on bone have yet to be established.
Microbiome
The healthy intestine contains an ecosystem of microorganisms,
comprised of more than 500 different species of bacteria, the
delicate balance of which affects numerous organs and systems
throughout the body. New research on the horizon involves study
of the relationship of CKD and the colonic microbiome, and
emerging evidence suggests that alterations in the microbiome
occur that may contribute to derangement of bone and mineral
metabolism. In the colon, anaerobic bacteria ferment undigested
protein to produce a variety of potentially toxic metabolites,
including indoles; these metabolites accumulate as renal func-
tion deteriorates. Indoles are absorbed and further metabolized
to indoxyl sulfate in the liver (43). Indoxyl sulfate was shown to
induce skeletal resistance to PTH by inducing osteoblast dysfunc-
tion in vitro, and prevention of accumulation of indoxyl sulfate
improved bone formation in animal studies (44, 45). Further stud-
ies are needed to investigate the implications of microbiome alter-
ations in CKD and potential future therapeutic targets in this area.
POST-TRANSPLANT
Many children come to transplant with deranged bone health
related to CKD. After transplant, recovery of bone health may
be impaired by nutritional vitamin D deficiency, persistent
hyperparathyroidism, tertiary FGF-23 excess, hypophosphatemia,
immunosuppressive therapy with corticosteroids and/or cal-
cineurin inhibitors (CNI), and alteration of sex hormones. The
incidence of vertebral fracture in children after kidney transplanta-
tion is 140 times higher than the general population (46). Bone his-
tomorphometry of pediatric kidney transplant recipients showed
that defective skeletal mineralization was present in 34% (47).
Recent studies measuring BMD by DXA have demonstrated that
low BMD is common in pediatric renal transplant recipients (3,
8, 9). A recent study used pQCT to examine changes in trabecular
and cortical volumetric BMD and cortical dimensions in children
and adolescent renal transplant recipients for 12 months post-
transplant, and found persistent deficits in cortical dimensions,
and reduced trabecular BMD in the older recipients (2).
NUTRITIONAL VITAMIN D DEFICIENCY
The prevalence of nutritional vitamin D deficiency among pedi-
atric transplant recipients is high and more common compared to
healthy controls (16). Recent studies report deficiency in 22–38%
and insufficiency in 32–54% of transplanted children (3, 16, 48,
49). The role of vitamin D in bone mineralization and growth dur-
ing childhood and adolescence is well established. In the pediatric
renal transplant population, vitamin D deficiency has also been
shown to correlate with hyperparathyroidism, short stature, and
hypophosphatemia (48, 49). Studies show that nutritional vitamin
D supplementation improves BMD in adults in both the general
and renal transplant populations (50–52).
INCREASED PTH, FGF-23, AND HYPOPHOSPHATEMIA
The phenomenon of early post-transplant hypophosphatemia
related to decreased phosphorus reabsorption in the proximal
tubule is well known, and persistence of hypophosphatemia in
long-term kidney transplant recipients has been recently charac-
terized (53–55). Excess of both FGF-23 and PTH have been found
to contribute to post-transplant hypophosphatemia. However,
there is controversy about whether PTH or FGF-23 plays a domi-
nant role in post-transplant hypophosphatemia. In the early post-
transplant period, Evenepoel et al. demonstrated that elevated
pre-transplant FGF-23 levels were the strongest predictor of post-
transplant elevation of FGF-23, and FGF-23 independently pre-
dicted hypophosphatemia and inappropriately low 1,25-(OH)2D3
levels during the first 3 months post-transplant (56). Further stud-
ies are needed to elucidate the pathogenesis of persistent long-term
post-transplant hypophosphatemia, as some studies have reported
that persistent hyperparathyroidism has a greater influence than
FGF-23, while others suggest that FGF-23 is the main driving force
behind the persistent dysregulation of phosphate homeostasis (53,
55, 57). In children with chronic allograft nephropathy, FGF-23
levels increase with the degree of chronic allograft failure, pre-
ceding increase in PTH, suggesting that FGF-23 may be a more
sensitive biomarker of post-transplant phosphorus dysregulation
and continuation or reactivation of CKD–MBD (55).
Persistent renal phosphate wasting in the setting of long-
term post-transplant hypophosphatemia contributes to decreased
osteoblast activity and progressive bone demineralization, increas-
ing the risk of low BMD over time (58). More research is needed to
determine the relationships between PTH, FGF-23, and hypophos-
phatemia with TMV bone parameters, and to identify possible
therapeutic targets. There is also need for determining the optimal
serum phosphorus level to maintain adequate bone mineralization
after transplant.
HYPOMAGNESEMIA
Hypomagnesemia is common after kidney transplantation, related
to magnesium wasting secondary to use of CNI. Magnesium is
an integral component of the hydroxyapatite structure of bone,
and is essential for the physiological function of osteoblasts and
osteoclasts and regulation of PTH. Magnesium deficiency con-
tributes to osteoporosis by acting on crystal formation and bone
cells impairing the magnesium dependent hydrogen-potassium-
ATPase pump within the cells of the periosteum, leading to
decreased pH of extracellular bone fluid and increased bone
demineralization. Magnesium deficiency has numerous effects on
PTH regulation, which include impairing PTH secretion, induc-
ing PTH resistance and decreasing production of 1,25-(OH)2D3
(59). In addition, hypomagnesemia has been reported to cause
hyperparathyroidism in some studies. The mechanism of action
of magnesium in modulating excess PTH secretion mimics that
of calcium at the calcium sensing receptor of the parathyroid
glands. Indeed, a prospective long-term study of renal transplant
recipients showed that hypomagnesemia at 5 years post-transplant
is an independent predictor of persistent hyperparathyroidism
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(54). Low magnesium levels have been linked with decreased
BMC and BMD in malnourished children (60), and magnesium
supplementation resulted in increased accrual of bone mass in
peripubertal girls with suboptimal dietary magnesium intake (61).
EFFECT OF IMMUNOSUPPRESSION
All maintenance immunosuppressive therapies have been impli-
cated in causing impairment of bone health in children after
transplant. Corticosteroids inhibit bone formation by decreasing
gastrointestinal calcium absorption, reducing osteoblast prolifera-
tion, inducing osteoblast apoptosis, impairing osteoblast function
via interference with the GH/IGF-1 axis, and promoting osteo-
clastogenesis; these changes result in decreased bone formation,
bone loss, and increased risk for fractures (62). A study of changes
in BMD after renal transplant in children reported decreased
trabecular and increased cortical BMD associated with greater
glucocorticoid exposure, reflecting the preferential depletion of
trabecular bone volume fraction by glucocorticoids (2). A large
case–control study of over 37,000 children treated with four or
more courses of oral corticosteroids found that, compared to con-
trols, corticosteroid-treated children had an adjusted odds ratio
for fracture of 1.32 (63). The introduction of steroid avoidance
protocols in the early 2000s has resulted in a decrease in the use
of post-transplant steroid immunosuppression therapy by almost
20%, according to an analysis of the North American Pediatric
Renal Trials and Collaborative data over 20 years. In this analysis of
over 10,000 pediatric transplant recipients, growth improved with
steroid avoidance, height Z -score remained stable with alternate
day steroid therapy, and declined with the daily use of steroids (64).
CNI medications, such as tacrolimus and cyclosporine, also
exert negative effects on bone by inhibiting synthesis of the
vitamin D receptor and osteoprotegerin and stimulating osteo-
clast differentiation (65). Tacrolimus and cyclosporine have been
linked to osteoporosis in adult renal transplant recipients (66).
In addition, CNI have been associated with post-transplant bone
pain syndrome, possibly due to intraosseous vasoconstriction and
ischemia (67). Evidence from in vitro and animal studies indi-
cate that mammalian target of Rapamycin (mTOR) inhibitors
including sirolimus and everolimus may also impair bone for-
mation and growth by interfering with osteoblast proliferation
and inhibiting growth plate structure and function (68, 69). Rats
treated with sirolimus showed signs of decreased bone longitu-
dinal growth rate, reduced chondrocyte proliferation, disturbed
chondrocyte maturation, decreased cartilage resorption, and mor-
phological evidence of altered vascular invasion in the growth plate
(69). However, in a recent clinical trial, longitudinal growth over
2 years in steroid-free pediatric patients on low-dose everolimus
and cyclosporine was not different to that of a matched steroid-free
control group on an immunosuppressive regimen with standard-
dose CNI and mycophenolate mofetil. Further studies are needed
to elucidate the effect of mTOR inhibitors on bone (70).
ROLE OF SEX HORMONES
Delayed sexual maturation may remain a problem after kidney
transplantation, impeding improvements in bone development
and mineralization post-transplant. A study assessed sexual matu-
ration of pediatric kidney transplant recipients by Tanner staging
and found that the age of onset of puberty was significantly delayed
in the transplant recipients compared with controls (28). Delayed
sexual maturation was present in 22.2% of girls and 19.1% of
boys, and was related to lower levels of sex steroids in these trans-
plant recipients. Delayed post-transplant sexual maturation may
be attributed in part to glucocorticoid therapy, which is known to
reduce the production of sex hormones and interfere with bone
maturation by impairing differentiation of the growth plate (71).
Thus, in patients receiving steroid therapy after kidney transplan-
tation, improvements in bone maturation and growth may not
occur (25).
ROLE OF MICROBIOME
After transplant, a variety of factors may continue to impact
the gastrointestinal microbiota. Prophylactic antibiotic therapy
induces modification of gut flora that results in reduction in min-
eral solubility, absorption, and decreased mineral deposition in the
skeleton (72). Early evidence suggests that treatment with prebi-
otics and probiotics may counteract antibiotic-induced effects by
restoring the colonic microbiota and cecal pH, stimulating min-
eral solubility and absorption, and promoting improvement in
BMC and structure in both animals and humans (72). Probiotics,
including Bifidobacteria and Lactobacilli, have been accepted as
generally safe for use in healthy infants and children, but more
data are needed to establish safety for individual probiotic strains
in immunocompromised populations, such as pediatric transplant
recipients (73). Cases of bacterial sepsis related to probiotic use,
including Lactobacillus and Bifidobacterium strains, have been
reported in infants and children with underlying immune com-
promise or chronic disease, and therefore use in these patients
merits further study to establish safety and efficacy in the pediatric
transplant population (74, 75).
CURRENT AND FUTURE STRATEGIES FOR OPTIMIZATION OF
POST-TRANSPLANT BONE HEALTH
The optimization of bone health after transplantation can only be
achieved through regular monitoring and careful management of
the myriad of components that contribute to CKD–BMD, begin-
ning in the early stages of CKD, and continuing throughout ESRD,
at the time of renal transplant, and beyond.
EVALUATION AND MONITORING
Measurement of BMD in the first 3 months after kidney transplant
should be considered in patients who receive corticosteroids or
have risk factors for osteoporosis as in the general population (76).
Regular monitoring of serum calcium, phosphorus, total CO2,
alkaline phosphatase, PTH, and 25(OH)D should begin at stage
2 CKD and continue throughout the cycle of CKD, dialysis, and
transplantation (11). In the immediate post-transplant period, it
is recommended to monitor serum calcium and phosphorus levels
at least weekly, and thereafter, monitor these and other parameters,
including magnesium, based on the degree of abnormalities and
rate of progression of CKD (76).
PROMOTION OF HEALTHY DIET AND LIFESTYLE
Adequate dietary calcium intake during childhood and adoles-
cence is recommended for skeletal development and acquisition
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Table 1 | Dietary reference intakes (DRI) for calcium and phosphorus (77).
Age Calcium DRI
(mg/day)
Phosphorus DRI
(mg/day)
Copper DRI
(mcg/day)
Zinc DRI (mg/day)
female/male
Magnesium DRI (mg/day)
female/male
0–6 months 200 100 200 2 30
6–12 months 260 275 220 3 75
1–3 years 700 460 340 3 80
4–8 years 1000 500 440 5 130
9–13 years 1300 1250 700 8 240
14–18 years 1300 1250 890 9 (F)/11 (M) 360 (F)/410 (M)
of bone mass; however excessive calcium should be avoided, as
positive calcium balance contributes to development of soft-tissue
calcifications. KDOQI guidelines advise adequate dietary intake of
calcium, phosphorus, and vitamin D to meet at least 100% of the
DRI for age, and not to exceed 200% of the DRI for age for calcium
(Table 1) (12). The recommended daily intake for vitamin D is 400
international units for infants and 600 international units for ages
1–30 years of age. It is recommended that exclusively breast fed
infants as well as those taking <1000 mL/day of fortified formula
should be supplemented with 400 international units of vitamin
D daily (77).
Guidelines currently recommend a high phosphorus diet and
oral phosphate supplementation for children with persistent post-
transplant hypophosphatemia. However, more recent data suggest
that oral phosphate supplementation may be ineffective in correct-
ing post-transplant hypophosphatemia, as it further stimulates
FGF-23 secretion. Research and development of novel therapies
are needed. Anti FGF-23 antibodies have been shown to lower
FGF-23 levels and improve hypophosphatemia in animal studies
and may be an area of further research to improve bone mineral-
ization after transplant (78). In another animal study, an FGF-23
receptor inhibitor was used to block the FGF-23 receptor, result-
ing in significantly lower FGF-23 levels compared with control
animals, representing another possible therapeutic option (79).
For promotion of bone health, adequate dietary intake to meet
100% of the DRI for minerals that affect bone health, including
copper, zinc, and magnesium, is recommended (Table 1) (12).
Post-transplant hypomagnesemia should be corrected with oral
magnesium supplementation to achieve and maintain magnesium
homeostasis and promote optimization of BMD (12, 59).
Following a low sodium diet has been shown to promote ben-
eficial skeletal effects, while high sodium intake increases urinary
calcium excretion and loss of calcium from bone, decreases bone
formation, and is associated with reductions in plasma calcium
and 1,25-(OH)2D3 (80). Because BMD is inversely related to
sodium intake, and additionally as hypertension is common after
transplant, pediatric renal transplant recipients may benefit from
limiting sodium intake to no more than 2000 mg/day. Interest-
ingly, omega-3-fatty acids were shown to counteract the bone
alterations induced by high salt intake, evidenced by increased
bone mass and formation and decreased bone resorption and bone
loss in omega-3 fatty acid supplemented rats on a high salt diet,
compared with rats on high salt diet alone (80). These benefi-
cial effects of omega-3 may be attributed to its positive effects on
calcium, phosphorus, and alkaline phosphatase homeostasis, and
could provide a non-toxic therapeutic option if proven effective in
human studies.
Avoidance of cola beverages is also recommended. The intake of
cola beverages has been linked with decreased BMD and increased
fracture risk in the pediatric population, and with increased risk
of osteoporosis in adult women. In animal studies, cola-fed rats
displayed decreased osteogenesis, delayed bone formation, and
thinner trabecule compared with controls (81). Possible contrib-
utors to the deleterious effects of excess cola consumption on
bone may include the replacement of more nutrient-rich foods
and beverages in the diet by cola, reduction of vitamin D syn-
thesis and calcium absorption by the phosphoric acid in the cola,
and/or accelerated bone resorption induced by the acid load of
the cola. The fructose in cola may also compromise bone health
in growing children, based on data demonstrating decreased lev-
els of 1,25-(OH)2D3, decreased bone length and bone ash, and
increased FGF-23 levels in growing fructose-fed rats. In this study,
the decreased 1,25-(OH)2D3 levels were associated with reduc-
tion in calcium transport rate and expression of intestinal and
renal calcium transporters (82).
Weight-bearing exercise plays a key role in maintaining bone
mass throughout life, and is important for promoting bone health
and strength after transplant. Bones strengthen in response to
mechanical loading forces, but weaken if not subjected to load-
ing and weight bearing for sufficient periods of time. Moderate
weight-bearing physical activity of a minimum of 30 min on most
days of the week, to include short bouts of high-impact activity
such as skipping or jumping, is recommended to promote increase
or preservation of bone mass (24).
CORRECTION OF VITAMIN D DEFICIENCY AND PTH ABNORMALITIES
Nutritional vitamin D deficiency/insufficiency should be treated
with oral supplementation, both before and after renal transplan-
tation, however the optimal treatment regimen is not known.
Guidelines for the pediatric CKD population have been estab-
lished (Table 2) (12). There are presently no specific guidelines for
the pediatric transplant population. The level of vitamin D suffi-
ciency is not well defined, with the target levels varying from >20
to 30 ng/mL (4, 12, 83). There is some evidence to suggest that
cholecalciferol is more effective than ergocalciferol for repletion
of vitamin D (3, 84).
Parathyroid hormone levels should be maintained within the
target range based on stage of CKD (Table 3). As allograft function
declines, 1,25-(OH)2D3 should be initiated if nutritional vitamin
D is replete and PTH is above the target range for CKD stage (11).
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Table 2 |Treatment for 25-hydroxy vitamin D insufficiency/deficiency
in CKD (12).
25-Hydroxy vitamin D
level (ng/mL)
Cholecalciferol treatment dose
<5 8000 IU/day×4 weeks, then 4000
IU/day×8 weeks
5–15 4000 IU/day×12 weeks
16–30 2000 IU/day×12 weeks
Table 3 |Target range of PTH for stage of CKD (11).
CKD stage Target serum PTH (pg/mL)
2–3 35–70
4 70–110
5 200–300
Correction of metabolic acidosis
Metabolic acidosis after kidney transplantation may occur due
to CNI effects and acute rejection, and contributes to post-
transplant abnormalities in calcium and phosphorus metabolism
and disorders of bone remodeling via skeletal buffering of excess
protons. Acidosis should be corrected and CO2 level maintained
≥22 mEq/L to promote resolution of electrolyte abnormalities,
decrease the risk of post-transplant osteoporosis, and maximize
growth (19).
Recombinant human growth hormone therapy
Recombinant human growth hormone (rhGH) therapy has been
established as an effective therapy for improvement of growth
velocity in children with CKD, including those post-transplant
(85, 86). More recent studies have investigated the effects of rhGH
on bone mineralization. A study of infants with CKD found that
those treated with rhGH for 12 months had improved BMD, evi-
denced by a 39% increase of radius mineral density compared
with baseline (87). Another study evaluated BMD distribution in
children and adolescents with ESRD on dialysis using quantitative
backscattered electron imaging of paired bone biopsy specimens
and found that 1 year of therapy with rhGH resulted in improved
growth and histomorphometric indices of bone formation rate,
suggesting improved bone matrix mineralization (88). Data on
the relationship between rhGH and BMD in the pediatric trans-
plant population are scarce. One study of pediatric renal transplant
recipients found that treatment with rhGH maintained vertebral
bone mass, whereas modest decrease in bone mass were observed
in untreated control subjects (89). Recent analysis of a large ret-
rospective pediatric cohort indicated that rhGH is not associated
with increased risk of post-transplant lymphoproliferative disor-
der (90), however, some data suggest rhGH may increase the risk
of acute rejection, thus further investigation of safety of rhGH in
the pediatric transplant population may be warranted (86).
Steroid avoidance
Kidney disease improving global outcome guidelines recommend
minimizing or avoiding corticosteroid use in children who still
have growth potential (76). A recent analysis of the United States
Renal Data System data (n= 77430) reported that adult kidney
transplant recipients on early steroid withdrawal protocols (dis-
charged without corticosteroids) had a 31% lower fracture risk
compared to those discharged with corticosteroid therapy (62).
Prospective randomized clinical trials in pediatric kidney trans-
plant recipients have shown that steroid avoidance protocols are
safe and are associated with improved in growth in pre-pubertal
recipients followed for up to 36 months post-transplant (91, 92).
However, one prospective pediatric study showed that steroid min-
imization alone was not effective in preventing post-transplant
bone mineral loss (93). The continued development of strategies to
minimize steroid exposure in the pediatric transplant population
is important.
Drug therapy
The KDIGO guidelines recommend consideration of vitamin
D analogs or bisphosphonates to treat bone disease during the
first year post-transplant in adults (4). Very little data is avail-
able on the safety and efficacy of treatment of post-transplant
bone disease with vitamin D analogs and bisphosphonates in
children. In a 2-year long randomized double-blind controlled
trial of 34 children with osteogenesis imperfecta, bisphospho-
nate treatment was associated with a 31% reduction in relative
risk of fracture of long bones, greater increase in spinal BMC
and BMD compared with placebo (94). In the pediatric trans-
plant population, a study of 30 pediatric transplant recipients
with low BMD showed improved lumbar spine BMD after treat-
ment with a 1,25-(OH)2D3 analog compared with placebo (95). In
another study, pediatric transplant recipients treated with either
alfacalcidol, alendronate, or calcitonin for 1 year demonstrated
consistent improvement in BMD with all therapies compared to
an untreated control group (96). Grenda et al. compared effect
of three different interventions [prophylactic oral ibandronate
with steroids, daily 1,25-(OH)2D3 supplementation with steroids,
or steroid minimization] on the long-term BMC and BMD of
pediatric renal transplant recipients. In this study, the patients
who received the prophylactic ibandronate maintained BMC and
BMD over the 2-year period, while those receiving 1,25-(OH)2D3
or steroid minimization demonstrated significant decrease in
BMD (93).
In adult transplant recipients, testosterone and estrogen
replacement have been shown to slow bone loss (67). KDOQI
guidelines for adult transplant recipients suggest that therapy with
replacement of gonadal steroid hormones for estrogen-deficient
and testosterone-deficient patients should be seriously considered
after kidney transplantation (19).
Teriparatide, a recombinant human PTH, is a potential
treatment option in adult transplant recipients with low PTH
and refractory hypocalcemia (97). Denosumab, a RANK-ligand
inhibitor, inhibits the maturation of osteoclasts to protect bone
from degradation, and is approved for treatment of osteoporosis
in post-menopausal women, and can be used in post-menopausal
women with stages 1–3 of CKD (98).
Presently, there is insufficient evidence to guide use of these
drug therapies to treat bone disease in pediatric kidney transplant
recipients.
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Microbiome
Strategies to reestablish symbiosis of the colonic microbiome are
under investigation and may hold promise as a new frontier in
the development of future therapeutic interventions. Aims of
potential therapies that may promote improvement in bone health
include restoration of the bacterial milieu of the colon, reduction
of generation of bacterial toxins in the colon, or adsorption of the
toxic end products of microbial fermentation within the colon.
In the general pediatric population, supplementation of infant
formula with the probiotic Bifidobacteria reduced stool pH and
decreased fecal ammonia and indoles in healthy infants (99, 100).
In the adult CKD and dialysis populations, prebiotic and probiotic
therapies were shown to reduce serum concentrations of the toxin
indoxyl sulfate, thereby promoting improved bone formation (43,
101). A vegetarian diet was also recently associated with lower
production of indoxyl sulfate in healthy adults (102). Adsorption
therapy using AST-120, an oral carbon-based adsorbent material,
was shown to reduce serum indoxyl sulfate levels in animals, as
well as in adult CKD patients, but requires further study (103,
104). There are no published studies investigating the effects of
these therapies in pediatric CKD or dialysis populations, and ther-
apies targeting the colonic microbiota of the pediatric transplant
population also remain an unexplored area.
CONCLUSION
The accrual of optimal bone mass during childhood and adoles-
cence is the best protection against development of osteoporosis
later in life (1), however achieving this in children with CKD is
challenging. Loss of kidney function engenders a chain of distur-
bances in endocrine and mineral metabolism that require precise
monitoring and management in order to preserve bone health.
After transplantation, new factors, including effects of immuno-
suppressive therapies pose continued threats to bone. Little is
known about effective therapies for treatment of bone disease in
the pediatric CKD and transplant patients, therefore continued
efforts toward research and discovery in this field is critical for
improving bone health of this population.
KEY POINTS
• Disturbances in mineral metabolism and endocrine homeosta-
sis begin early in the course of CKD, leading to CKD–BMD, and
impaired growth in children.
• Risk factors for CKD–MBD include nutritional vitamin D
deficiency, secondary hyperparathyroidism, increased FGF-23,
altered GH/IGF-1 axis, delayed puberty, malnutrition, and
metabolic acidosis.
• After kidney transplantation, nutritional vitamin D defi-
ciency, persistent hyperparathyroidism, tertiary FGF-23 excess,
hypophosphatemia,hypomagnesemia, immunosuppressive ther-
apy, and alteration of sex hormones continues to impair bone
health and growth.
• Bone biopsy is the gold standard for evaluation of bone qual-
ity, which should be defined by assessment of bone turnover,
mineralization, and volumetric parameters. DXA and pQCT are
non-invasive options, but carry limitations.
• Optimal target ranges for combinations of traditional bio-
markers (serum calcium, phosphorus, PTH, and alkaline
phosphatase), and newer biomarkers, such as FGF-23, to predict
bone quality need to be investigated.
• Strategies to optimize bone health post-transplant include
healthy diet, weight-bearing exercise, correction of vitamin
D deficiency, acidosis, and electrolyte abnormalities, steroid
avoidance, and consideration of rhGH therapy when indicated.
• Drug therapies including vitamin D analogs, bisphospho-
nates, hormone replacement, teriparatide, denosumab, and cal-
cimimetics have been used in adult transplant recipients, but
there is insufficient evidence for use in the pediatric population
at the present time.
• Future therapies to be explored include anti-FGF-23 antibodies,
FGF-23 receptor blockers, and treatments targeting the colonic
microbiota by reduction of generation of bacterial toxins or
adsorption of toxic end products that affect bone mineralization.
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